Microsoft Adds Another Gaming Studio to Its Portfolio
Microsoft aims to acquire ZeniMax Media and its game publisher, Bethesda Softworks, bringing Elder Scrolls, Doom, Fallout and Wolfenstein under its banner.
All Work
Chris Lange
PMV Pharmaceuticals Closes in on IPO
Precision oncology company PMV Pharmaceuticals intends to price more than 7.35 million shares for an initial public offering valued up to around $152 million.
KB Home, Nike, Stitch Fix, Rite Aid and More Earnings Coming This Week
24/7 Wall St. has previewed Nike, Rite Aid and some of the other key companies expected to report quarterly results this week.
This Week in Coronavirus News
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which…
Unity Software Enters the Market With a Bang
San Francisco-based Unity Software entered the market with a bang on Friday.
Why This Cancer Detection IPO Could Be a Big Hit
Cancer-detection-focused health care company Grail has filed with the SEC, regarding its initial public offering.
Rigel Pharma Moves Forward With Midstage COVID-19 Study
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of COVID-19.
Sorrento Therapeutics Wins FDA Approval to Proceed With COVID-19 Study
Sorrento Therapeutics shares jumped on Thursday after the company announced that it received approval from the FDA for its COVID-19 treatment.
5 Turnaround Stocks Getting Some Traction on Wall Street
Analysts, investors and Wall Street gurus seem to think the worst is over and companies that were beat up initially may be in a sweet position down the line. Here are five companies that…
Snowflake Enters the Market With a Bang
Shares of data warehousing cloud service provider Snowflake entered the market with a bang on Wednesday.
What Analysts Are Saying About FedEx After Earnings
Analysts cheered the FedEx first-quarter fiscal 2021 financial results report, as many are chasing it higher with their target hikes.
Why This Interim Liver Study Is Huge for Arrowhead Pharma
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.
What’s Going on in Adobe’s Record Quarter
Adobe reported fiscal third-quarter earnings after markets closed Tuesday and posted $2.57 in earnings per share (EPS) and a record $3.23 billion in revenue, both better than analysts' expectations.
Why FedEx’s Q1 Is So Impressive
FedEx reported fiscal first-quarter 2021 financial results after markets closed Tuesday. The company crushed both top- and bottom-line estimates.
Why This Epilepsy Study Is Huge for Marinus Pharmaceuticals
The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals shares on Tuesday.
Laird Superfood Announces Potential Pricing for IPO
Laird Superfood intends to price more than 2 million shares for an initial public offering valued up to over $50 million.
Why This FDA Win for Ardelyx Is Definitely a ‘Sell the News’ Moment
Companies winning approval from the FDA or beating a trial are expected in some cases. If investors already have priced this news into the stock, when it actually comes around they tend to sell…
How Cassava Sciences Could Be Pioneering a Groundbreaking Alzheimer’s Treatment
Cassava Sciences reported good results from a mid-stage study of its sumifilam treatment for Alzheimer's disease. Shares soared on the news.
Is the Turnaround at GameStop Sustainable After 2020?
Has video game retailer GameStop broken out of the downward spiral that had captured it for so long? Two analysts are optimistic about the company's near-term outlook.
Caledonia Rolls the Dice on Scientific Games With Massive Stake
Scientific Games was one of Monday’s big winners after the company announced that it had reached an agreement with a credentialed gaming industry investor to buy a significant stake in the company.